Cancer Communicator | Cancer Conference Hub #CancerNews
Feed on Bluesky
www.onclive.com
Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma | OncLive
Belantamab mafodotin plus lenalidomide maintenance was active and had an expected safety profile in transplant-eligible, newly diagnosed myeloma.
www.onclive.com
Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma | OncLive
Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.
www.onclive.com
ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma | OncLive
Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.
www.onclive.com
Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma | OncLive
Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.
www.onclive.com
Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma | OncLive
Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.
oncodaily.com
Highlights from the 22nd IMS Annual Meeting - OncoDaily
Highlights from the 22nd IMS Annual Meeting / cancer, IMS 2025, International Myeloma Society, multiple myeloma, Myeloma, Myeloma Society, OncoDaily,
www.onclive.com
Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma | OncLive
Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.
www.onclive.com
Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma | OncLive
The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.
www.onclive.com
Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma | OncLive
Daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.
Sara R. Fagerlie, PhD, CHCP 
